## HCA: HCA Healthcare, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -1.0% below STRENGTH zone (3.0-6.0%); PEG 1.29 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge.

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($444.90)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 3, Bearish: 2)

**1. Morgan Stanley downgrades HCA Healthcare stock on peak valuation concerns**
- Source: Investing.com India | 20251215T090207 | Bearish | Relevance: 100%
- Morgan Stanley downgraded HCA Healthcare Inc (NYSE:HCA) from Equalweight to Underweight, setting a price target of $425.00 due to significant stock outperformance and peak valuation multiples. Despite the company's strong execution and shareholder-friendly capital allocation, including substantial share buybacks, the firm warns of potential deceleration in HCA's stock as tailwinds from healthcare policies are expected to ease. HCA's stock has risen 62% year-to-date in 2025, but trades at a high P/E ratio of 18.7 relative to its near-term earnings growth potential.

**2. Hound Partners LLC Sells 3,535 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251214T122523 | Bullish | Relevance: 100%
- Hound Partners LLC has reduced its stake in HCA Healthcare by 10%, selling 3,535 shares and retaining 31,832 shares valued at approximately $12.2 million. Despite this, institutional ownership of HCA remains high at 62.7%, with several other large institutions increasing their positions. HCA has also reported strong quarterly earnings, raised FY2025 guidance, and maintains a "Moderate Buy" consensus rating from analysts.

**3. Public Sector Pension Investment Board Sells 11,216 Shares of HCA Healthcare, Inc. $HCA**
- Source: MarketBeat | 20251214T105533 | Somewhat-Bullish | Relevance: 100%
- The Public Sector Pension Investment Board reduced its holdings in HCA Healthcare, Inc. by 6.5% during the second quarter, selling 11,216 shares. Despite this, other institutional investors like Norges Bank, Price T Rowe Associates Inc. MD, and Viking Global Investors LP significantly increased their stakes in the company. HCA Healthcare recently posted strong earnings, beating analyst consensus, and declared a quarterly dividend of $0.72 per share.

**4. Why HCA Healthcare (HCA) is a Top Growth Stock for the Long-Term**
- Source: www.sharewise.com | 20251216T214257 | Bullish | Relevance: 100%
- HCA Healthcare (HCA) is identified as a top growth stock due to its strong financial health and promising future outlook, earning an "A" Growth Style Score and "A" VGM Score from Zacks. The company, a leading operator of acute care hospitals, is projected to see a 24.7% year-over-year earnings growth for the current fiscal year, with analysts revising estimates upwards. Investors looking for companies with high growth potential should consider HCA, particularly given its Zacks Rank #3 (Hold) combined with excellent Style Scores.

**5. HCA Healthcare Hits A High But Morgan Stanley Turns Cautious**
- Source: Finimize | 20251215T160841 | Somewhat-Bearish | Relevance: 100%
- Morgan Stanley has downgraded HCA Healthcare to 'underweight', causing a 2% drop in its share price. The downgrade comes after years of HCA outperforming the market, with analysts citing stretched valuations and the fading impact of post-pandemic patient surges and ACA enrollments as key reasons. This signals a potential shift in sentiment for the healthcare sector as a whole, which may face increased scrutiny.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-15 | Morgan Stanley | $425 | $425 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-15 | Morgan Stanley | down | Underweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 2 ($3.12M) |
| Sells | 4 ($14.79M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 29.8% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 2 / 7 |

**Top Holders:**
- Vanguard Group Inc: 6.5% (-3.8%)
- Blackrock Inc.: 5.5% (-3.7%)
- Sanders Capital, LLC: 4.7% (-3.9%)
- State Street Corpora: 3.3% (-5.9%)
- JPMORGAN CHASE & CO: 2.6% (+82.2%)

### Key Risks

1. Heavy insider selling: $15M sold (4 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.29 suggests fair value with growth premium. Forward P/E 15.8x stretched relative to 8% growth. Quality metrics strong (ROE 136%, ROA 12%). Balance sheet: $3.1B free cash flow. Insider selling cluster ($14.8M in 90 days), potential headwind. Institutional flow bullish (2 buying vs 7 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $109.9B |
| Beta | 1.37 |
| 52W Range | $289.98 - $520.00 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.29 |
| Forward P/E | 15.8 |
| Current P/E | 17.0 |
| YoY Growth | 7.6% |
| EPS Direction | RISING |

### Technicals

MRS_10 strengthening from -5.7% to -1.0% (+4.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 4.0pp (needs >3.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.19x) but short-term weakness (below SMA20). MACD histogram bearish (-4.32), momentum weakening. RSI neutral at 44. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -1.03% (CS: 26) | Neutral |
| RSI_14 | 44.2 | Neutral |
| MACD Histogram | -4.32 | Bearish |
| vs SMA20 | 0.960x | Below |
| vs SMA50 | 1.009x | Above |
| vs SMA200 | 1.194x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $469.78
- **Stop Loss:** $444.90 (5.3% risk)
- **Target:** $494.66 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 40
- **Position Value:** $18,791.20
- **Portfolio %:** 18.79%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with balanced risk positioning. VIX remains calm at 16.48 while breadth shows modest improvement to 52%, indicating neither euphoria nor distress. Mixed sectoral themes from energy weakness to AI expansion suggest stock-picking environment rather than broad directional moves.*

### Earnings

**Next:** 2026-01-23 (Est: $7.46)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $5.73 | $6.96 | +21.6% |
| 2025Q2 | $6.32 | $6.84 | +8.2% |
| 2025Q1 | $5.75 | $6.45 | +12.1% |
| 2024Q4 | $6.14 | $6.22 | +1.2% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*